Page 24 - Development Partnership News Today

A new Phase III trial has found that zoliflodacin can effectively treat the bacterial infection that has become resistant to nearly every available drug.

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterAnnounced positive...

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resi...

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial...

Antibiotic could turn the tide on drug-resistant form of the infection — if it’s used wisely. Antibiotic could turn the tide on drug-resistant form of the infection — if it’s used wisely.

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of...

Bringing Taiwan to the World and the World to Taiwan

Antimicrobial resistance was directly responsible for an estimated 1.27 million deaths in 2019.

Balasegaram is the executive director of Global Antibiotic Research and Development Partnership.

A Leland manufacturer earned top honors recently from the Export-Import Bank of the U.S. in Was